

30. (new) The method of claim 29, wherein the hematopoietic stem or progenitor cells have been enriched for the CD34+ phenotype.

31. (new) The method of claim 29, further comprising contacting the dendritic cells with a molecule selected from the group consisting of GM-CSF, IL-4, TNF- α , IL-3, c-kit ligand, fusions of GM-CSF and IL-3, CD40 ligand, and CD40 antibody.

32. (new) The method of claim 31, wherein the molecule is GM-CSF.

33. (new) The method of claim 31, wherein the molecule is TNF- α .

34. (new) The method of claim 31, wherein the molecule is c-kit ligand.

35. (new) The method of claim 31, wherein the molecule is CD40 ligand.

36. (new) The method according to claim 29 wherein the flt3-ligand is a recombinant human flt3-ligand.--

REMARKS

The specification has been amended to update the status of the priority documents and correct minor typographical errors. Applicants have also cancelled the non-elected claims in this divisional application, and presented additional claims drawn to the elected invention.

After amendment, claims 12-13 and 15-36 are pending. New claims 15-16, 19-22, and 25-28 are supported by, for example, claims 12-13 as originally filed. Claims 17-18, 23-24 and 36 find support at, for example, page 13, line 26. New claims 29 to 35 are supported throughout the application, but particularly by claims 8-9 and at page 8, lines 20-33. No new matter has been added.

CONCLUSION

Applicants submit that the claims of the present application are in condition for allowance and respectively request a notice to that effect. If the Examiner believes that any

117

Respectfully submitted,

Respectfully submitted,

